The main differentiation in the 3DMed offering vs. other nucleic acid PCR-based testing is (1) the rapid daily throughput, #1 worldwide; and (2) the influenza A and B tests combined with coronavirus testing. This is a clinically meaningful combination because of the extended flu season in most countries that will create additional doubt among healthcare providers regarding the cause of symptoms for patients. The fact that this will be available in one test is the very first worldwide. The manufacturer is one of the world's largest oncology NGS diagnostic service providers, serving over 100,000 cancer patients in past 3 years.